Report Highlights

U.S. Role in the Global Ankylosing Spondylitis Treatment Supply Chain

The United States occupies the dominant commercial and innovation node in the global ankylosing spondylitis treatment supply chain, accounting for an estimated 45% of total global AS therapy revenues. Branded biologics manufactured by AbbVie in North Chicago, Novartis in Switzerland (distributed through U.S. specialty networks), and UCB in Belgium enter the U.S. market as finished drug products, with final fill-finish operations and cold-chain distribution managed by third-party logistics providers including AmerisourceBergen and McKesson. The U.S. market sets global reference pricing benchmarks that directly influence launch sequencing and reimbursement negotiations in Europe and Japan.

The U.S. is primarily an import-dependent market for active pharmaceutical ingredients used in biologic AS therapies, sourcing bulk drug substance from European contract manufacturers including Lonza (Switzerland) and Samsung Biologics (South Korea). Domestic manufacturing of finished biologics is concentrated in Illinois, New Jersey, and Massachusetts. Specialty pharmacy distribution through Accredo Health, CVS Specialty, and Walgreens Specialty Pharmacy constitutes the critical last-mile supply chain node, managing cold-chain integrity, patient adherence programs, and payer authorization workflows that collectively determine market access for both branded and biosimilar AS therapies.

Growth Drivers for U.S. Ankylosing Spondylitis Trade and Production

Accelerating biosimilar entry is the primary structural driver reshaping AS treatment supply chains within the U.S. market. Following Humira biosimilar approvals, the FDA pipeline includes multiple secukinumab and ixekizumab biosimilar candidates targeting 2026–2028 launches, which will expand manufacturing sourcing from South Korean and Indian CDMOs into U.S. distribution networks. This biosimilar wave is compelling originator manufacturers to invest in next-generation formulations and subcutaneous device innovations to defend volume, driving capital expenditure in domestic fill-finish and device assembly operations concentrated in New Jersey and California.

Expanding diagnostic rates represent the second critical growth driver, with an estimated 2.7 million Americans carrying undiagnosed axial spondyloarthritis, of whom a significant fraction will eventually receive AS-specific treatment. Rheumatology workforce shortages are being partially offset by telehealth-enabled care pathways, which are expanding treatment initiation in underserved markets including the Southeast and Midwest. Additionally, JAK inhibitor label expansions for upadacitinib (AbbVie's Rinvoq) and tofacitinib (Pfizer's Xeljanz) in AS are creating new oral therapy demand that favors ambient-temperature supply chain logistics over cold-chain biologic distribution, meaningfully reducing last-mile costs for payers and pharmacy benefit managers.

Supply Chain Risks and Trade Barriers

The U.S. AS treatment supply chain carries significant concentration risk at the biologic drug substance level. Approximately 70% of bulk monoclonal antibody production for AS therapies entering U.S. distribution originates from fewer than six contract manufacturing organizations, with Samsung Biologics and Lonza together representing a critical single-region vulnerability. Any disruption to South Korean or Swiss manufacturing capacity — whether from regulatory action, geopolitical escalation, or facility-level quality events — would require 12–18 months to remediate through alternative CDMOs, given biologic batch validation timelines. The FDA's intensified biosimilar inspections post-COVID have already delayed two planned AS biosimilar launches by an average of nine months.

Payer-imposed step therapy mandates and prior authorization protocols function as de facto trade barriers within the U.S. domestic market, restricting patient access to newer IL-17A and JAK inhibitor therapies until TNF inhibitor failure is documented. These protocols, enforced by pharmacy benefit managers including Express Scripts and OptumRx, delay market uptake for innovator therapies by 6–18 months after commercial launch. Additionally, proposed importation frameworks under the Inflation Reduction Act's drug pricing provisions create uncertainty around AS biologic pricing floors, potentially disrupting the rebate architecture that currently funds patient assistance programs relied upon by an estimated 35% of commercially insured AS patients.

Trade and Investment Opportunities in U.S. Ankylosing Spondylitis Treatment

The most immediate commercial opportunity in the U.S. AS market lies in specialty pharmacy platform investments that can integrate prior authorization automation, cold-chain management, and patient adherence monitoring into a single-vendor solution for payers managing growing AS biosimilar formularies. Companies including Nuvation Bio and newer digital health entrants are targeting rheumatology care coordination as a high-value service layer. Strategic investors acquiring or partnering with specialty pharmacies holding existing rheumatology payer contracts stand to capture disproportionate dispensing volume as biosimilar AS therapies achieve formulary parity with branded biologics through 2026 and 2027.

Inbound foreign direct investment from South Korean and Indian biopharmaceutical manufacturers seeking U.S. manufacturing presence represents a structurally important opportunity driven by both commercial and regulatory imperatives. The FDA's preference for domestic or allied-nation manufacturing, reinforced through recent executive orders on pharmaceutical supply chain security, creates incentive structures favoring CDMO facility establishment in U.S. pharmaceutical manufacturing clusters in New Jersey, North Carolina, and Indiana. International AS biosimilar developers including Alvotech (Iceland) and Celltrion (South Korea) are actively establishing U.S. manufacturing partnerships to accelerate FDA approval timelines and satisfy payer requirements for domestic supply chain transparency, creating partnership opportunities for U.S.-based fill-finish operators.

Market at a Glance

Leading Market Participants

• AbbVie
• Novartis
• UCB
• Eli Lilly
• Pfizer
• Johnson & Johnson (Janssen)
• Amgen
• Sandoz
• Alvotech
• Celltrion

Regulatory and Trade Policy Environment

The U.S. AS treatment market operates under FDA oversight frameworks that govern both innovator biologic approvals and the 351(k) biosimilar pathway. The FDA's interchangeability designation — granted to Hadlima (Samsung Bioepis) and Cyltezo (Boehringer Ingelheim) for adalimumab — directly enables pharmacy-level substitution without prescriber intervention, a regulatory mechanism with no equivalent in Europe or Japan and one that fundamentally alters U.S. channel economics. The Inflation Reduction Act's Medicare drug price negotiation provisions, effective 2026 onward, target high-expenditure biologics including several AS therapies, compressing net pricing and accelerating payer interest in biosimilar substitution across government and commercial formularies alike.

The U.S. operates without a bilateral pharmaceutical trade agreement specifically governing AS therapy imports, meaning finished biologic products from Switzerland, Belgium, and South Korea enter under standard most-favored-nation tariff schedules. Recent executive orders directing the Department of Health and Human Services to develop pharmaceutical supply chain security frameworks have introduced compliance reporting requirements for manufacturers with greater than 50% foreign API sourcing, directly affecting AS biologic supply chains. State-level step therapy reform legislation — enacted in 28 states through 2024 — is progressively limiting PBM authority to mandate branded-to-biosimilar switches without clinical justification, creating a fragmented regulatory landscape that complicates national launch strategies for biosimilar AS entrants.

U.S. Ankylosing Spondylitis Treatment Supply Chain Outlook to 2032

Through 2032, the U.S. AS treatment supply chain will undergo a structural transition from a branded-biologic-dominated, cold-chain-dependent distribution model toward a dual-track system incorporating both biosimilar biologics and oral small-molecule therapies. JAK inhibitors — particularly upadacitinib, which achieved AS approval in 2022 — will represent the fastest-growing dispensing volume category by 2028, driving ambient-temperature logistics growth and reducing specialty cold-chain infrastructure requirements. This shift benefits retail pharmacy chains with existing ambient dispensing infrastructure, potentially displacing specialty pharmacies as the primary AS dispensing channel for a meaningful share of newly diagnosed patients by 2030.

Manufacturing localization pressure will intensify as FDA and executive branch pharmaceutical security initiatives incentivize domestic biologics production. At least three major AS biosimilar developers have announced U.S. fill-finish partnerships targeting operational capacity before 2028, with North Carolina's Research Triangle and New Jersey's pharmaceutical corridor identified as primary investment destinations. Concurrently, precision medicine initiatives targeting HLA-B27 genotyping and IL-23 pathway biomarkers will create demand for companion diagnostic supply chain integration with AS treatment protocols, introducing molecular diagnostic manufacturers as new nodes in the U.S. AS treatment supply chain architecture through the forecast period.